Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Generex Biotechnology Corp GNBTQ

Healthcare Biotechnology
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and... see more

Recent & Breaking News (EXPM:GNBTQ)

Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th

GlobeNewswire April 9, 2019

Generex Biotechnology Corporation Appoints Mark J. Prioletti to the Board of Directors

GlobeNewswire April 8, 2019

Generex Addresses Shareholder Concern Over 8-K and Quarterly Filing

GlobeNewswire April 4, 2019

Upmarket Deal at $2.50 Per Share Saves Generex Biotechnology Shareholders $14+ Million

GlobeNewswire March 29, 2019

Generex Biotechnology Partner Olaregen Therapeutix, Inc. Selected to Present a Formal Poster Session at Prestigious Diabetic Limb Salvage Meeting

GlobeNewswire March 26, 2019

USMJ and PURA Update Dividend Distribution Plans With PJET and NOUV To Include New Developments With WCVC and KALY

GlobeNewswire March 22, 2019

KALY Phase One Cannabis Extract COPD Research To Be Published This Friday, March 22, 2019

GlobeNewswire March 20, 2019

KALY Initiates Phase Two Cannabis Extract COPD Treatment Study

GlobeNewswire March 18, 2019

Generex Biotechnology Announces the Appointment of Chief Commercial Officer

GlobeNewswire March 12, 2019

KALY Cannabis Patent Featured In PURA Report On Progress Toward $5 Million Sales Goal

GlobeNewswire March 8, 2019

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Appointment of Vice President of Business Strategy

GlobeNewswire March 8, 2019

Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest

PR Newswire March 7, 2019

Generex Investor Conference Call Now Available Online

GlobeNewswire March 1, 2019

PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019

GlobeNewswire February 26, 2019

KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study

GlobeNewswire February 21, 2019

Generex Biotechnology Announces Investor Conference Call Agenda; Tuesday, February 26, at 11:00 A.M. Eastern

GlobeNewswire February 15, 2019

Generex Announces Appointment of Marshal Schictman, Esq. as Executive Vice President General Counsel and Corporate SEC Attorney

GlobeNewswire February 12, 2019

Generex Biotechnology Responds to Demand for Payment

GlobeNewswire February 4, 2019

KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview

PR Newswire February 1, 2019

KALY Releases Update Highlighting Potential In $14 Billion COPD Treatment Market and Additional Pharmaceutical Markets

GlobeNewswire January 30, 2019